Csl Behring Gmbh

Csl Limited

Zlb Behring Gmbh

Uwe Liebing

Stefan Schulte

Hubert Metzner

Volker Gawantka

Thomas Weimer

Annette Feussner

Gerhardt Kumpe

Wiegand Lang

Karlheinz Enssle

Ulrich Kronthaler

Wilfried Wormsbächer

Joerg Lemmer

Christina Bodenbender

Wilfried Wormsbacher

Hermann Karges

Jörg Lemmer

The invention relates to factor VIII compositions and their use.

Factor VIII formulation

The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

Modified coagulation factor VIIa with extended half-life

The present invention relates to a process for purifying fibrinogen, which comprises one or more process steps in which one or more contaminating proteins are depleted by negative chromatography and/or negative adsorption using cation exchanger, hydrophobic gel and/or dye gel. In addition, the invention relates to the fibrinogen which is obtained by the process of the invention and which is notable for improved stability, and to the production and use of pharmaceutical preparations comprising this fibrinogen.

Fibrinogen purification

The present invention relates to a novel storage-stable formulation for fibrinogen in liquid or viscous liquid form comprising divalent metal ions. The fibrinogen formulation may comprise other conventional formulation ingredients and particularly preferably comprises a complexing agent. The invention further relates to the production and use of the fibrinogen formulation of the invention.

Storage-stable, liquid fibrinogen formulation

Growing community of inventors

Coelbe, Germany

Uwe Liebing